Zai Lab Limited announced that the 2023 National Reimbursement Drug List (NRDL) released by China?s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.91 USD | -4.51% | +20.16% | -27.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.15% | 2.07B | |
+0.10% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-9.41% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- ZLAB Stock
- News Zai Lab Limited
- Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List